atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
A triple-action Formula for comprehensive respiratory relief
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
Subscribe To Our Newsletter & Stay Updated
